Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis

Table 1 Table summarizing the distribution of patients over fibrosis stages and their corresponding percentages

Stage of fibrosis	Number of patients (%)
F0	29 (40)
F0-F1	13 (18)
F2-F3	14 (19)
F3-F4	5 (7)
F4	12 (16)
Total	73 (100)

Table 2 Table summarizing distribution of fibrosis stages over two groups of ages

Patient’s age	Fibrosis stages
	F0	F0-F1	F2-F3	F3-F4	F4	Total
20-49	17	7	7	0	2	33
> 50	12	6	7	5	10	40
Total	29	13	14	5	12	73

Table 3 Table summarizing the P value of the studied characteristics

Characteristic	P value
Age	0.0036
Gender	0.23
ALT	0.71
AST	0.07
Albumin	0.44
Cholesterol	0.22
GGT	0.22
LDL	0.07
HDL	0.68
ALP	0.033
Triglycerides	0.57
Bilirubin	0.0001
Glucose	0.0063
Platelet count	0.0001
PT INR	0.0011
PTT	0.0054

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; PPT: Partial thromboplastin time.

Table 4 Table showing differences in stiffness scores, aspartate transaminase/alanine transaminase ratio, aspartate transaminase platelet ratio index, and Fib-4 scores between patients with mild to moderate fibrosis and those with advanced fibrosis (expressed as mean ± SD)

	< F2 (n = 42)	> F2 (n = 31)	P value
AST/ALT ratio	0.84 ± 0.47	1.31 ± 1.1	0.0029
APRI score	0.35 ± 0.26	1.08 ± 1.2	3.59 × 10-7
Fib-4 score	1.07 ± 0.73	3.41 ± 3.44	9.11 × 10-9

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; APRI: Aspartate transaminase platelet ratio index.